Form 4: Delcath Systems Director Aharon Gil Reports Stock Option Grant

Director Aharon Gil reports the acquisition of stock options in Delcath Systems, Inc.

Summary

• On May 23, 2024, Aharon Gil, a director of Delcath Systems, Inc., reported the acquisition of stock options.
• The stock options grant the right to buy 22,500 shares of common stock at an exercise price of $7.85.
• The options vest monthly at a rate of one-twelfth per month, starting May 23, 2024, contingent upon continued service as a director.
• The options expire 10 years from the grant date or two years from the last day of service, whichever is earlier.

Sentiment

Score: 6

Explanation: The document is a routine filing related to stock option grants, which is generally neutral. It indicates alignment of director interests with shareholders but doesn't provide significant positive or negative news.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one-twelfth per month is a typical arrangement to incentivize long-term commitment.
• Comparable companies in the biotech industry, such as Amgen or Gilead, also utilize stock options as part of their director compensation.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's long-term success.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the relatively small number of shares involved.

Key Dates